title: Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate.
abstract: The aim of this study was to determine the effects of alendronate (ALN) on osteoclastic resorption of beta-tricalcium phosphate (beta-TCP) and bone formation. beta-TCP blocks of 75% porosity, with or without ALN treatment, were implanted into cavities drilled in rabbit femoral condyles. New bone formation, residual amount of beta-TCP, and the number of tartrate-resistant acid phosphatase-positive cells were evaluated 2 weeks after surgery. The results show that local application of ALN at a concentration of 10(-2) to 10(-6)M reduced the number of osteoclasts on the surface of beta-TCP. New bone formation was also inhibited by ALN in a dose-dependent manner. Thus, inhibition of osteoclast formation resulted in reduced beta-TCP resorption and bone formation. These results suggest that osteoclast-mediated resorption plays an important role in bone formation and a coupling-like phenomenon could occur in beta-TCP-filled bone defects.
authors: Department of Orthopaedic Surgery, NHO Utsunomiya National Hospital, Utsunomiya City, Tochigi, Japan. tanakat@e-utunomiya.hosp.go.jp
authors: Takaaki
authors: T
authors: Tanaka
authors: Mitsuru
authors: M
authors: Saito
authors: Masaaki
authors: M
authors: Chazono
authors: Yoshio
authors: Y
authors: Kumagae
authors: Takahiro
authors: T
authors: Kikuchi
authors: Seiichiro
authors: S
authors: Kitasato
authors: Keishi
authors: K
authors: Marumo
mesh_terms: D019386:Alendronate / Q000494:pharmacology*; D000818:Animals; D001672:Biocompatible Materials / Q000378:metabolism; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001862:Bone Resorption / Q000378:metabolism*; D001842:Bone and Bones / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D002130:Calcium Phosphates / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D020007:Implants, Experimental; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects*; D011817:Rabbits
chemical_list: D001672:Biocompatible Materials; D050071:Bone Density Conservation Agents; D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate; D019386:Alendronate